MIT researchers engineered ligand-directed lipid nanoparticles designed to reprogram natural killer cells in vivo into CAR-bearing cancer killers without viral vectors. In preclinical animal experiments, the approach achieved high-efficiency cellular engineering directly inside living animals, aiming to streamline CAR-NK manufacturing and improve access to potent off-the-shelf-style biology.